Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Collaborates With Broad Institute

by Ann M. Thayer
December 3, 2012 | A version of this story appeared in Volume 90, Issue 49

Roche’s Translational & Clinical Research Center will work with the Broad Institute of MIT and Harvard University in a multiyear collaboration to repurpose, or find new therapeutic uses for, existing Roche compounds. The Swiss drug firm is providing more than 300 compounds that failed to meet Phase II clinical milestones or were shelved for strategic reasons (C&EN, Oct. 1, page 15). Broad will use its screening technologies to try to link the compounds to novel patient populations, find new disease associations, or reveal new targets for drug discovery.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.